Cogent Biosciences, Inc. (COGT): Total Liabilities
$301.24M
As of 2025-12-31
$302.16M
As of 2026-06-30
+88.4%
3-year compound annual growth
+79.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $301.24M | +320.7% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $71.61M | +28.7% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $55.63M | +23.4% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $45.08M | +151.7% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $17.91M | +10.2% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $16.25M | -8.0% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $17.66M | -31.3% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $25.69M | +23.5% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $20.81M | n/a | 2019-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | 2025-12-31 | $301.24M | +320.7% |
| Praxis Precision Medicines, Inc. (PRAX) | 2025-12-31 | $59.77M | +58.7% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $3.01B | +26.7% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $44.74M | +15.5% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.91M | -13.7% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $528.12M | +18.6% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $188.85M | +17.3% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $415.23M | +16.9% |
Compare COGT, PRAX, BBIO, VRDN side by side · Screen every company in Pharmaceutical Preparations ↗